What do systematic reviews say?

Opioid antagonists vs placebo

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 77 participants
  Low

Mood stabilisers vs placebo

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 71 participants
  Very low

Atypical antipsychotics vs placebo

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 21 participants
  Very low

Antidepressants vs opioid antagonists

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 62 participants
  Very low

Antidepressants vs mood stabilisers

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 58 participants
  Very low

Antidepressants vs placebo

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 90 participants
  Low

Opioid antagonists vs mood stabilisers

• Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Augmentation of current antidepressant (various) with quetiapine (150 mg/d to 300 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 977 participants
  High

Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d)

Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 102 participants
  Low

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low
• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 20 participants
  Low

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Moderate

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 431 participants
  High

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 808 participants
  High

Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 199 participants
  Moderate

Tricylic antidepressant vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 30 participants
  Very low

Selective serotonin reuptake inhibitors vs placebo

• Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 148 participants
  Very low